Development of antiviral therapy for severe acute respiratory syndrome
| Autor: | Martin Michaelis, Gerold Hoever, Wolfgang Preiser, Hans Wilhelm Doerr, Jindrich Cinatl |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
medicine.medical_specialty
Anti-viral therapy Disease Severe Acute Respiratory Syndrome Antiviral Agents Article Disease Outbreaks chemistry.chemical_compound Virology Ribavirin medicine Animals Humans Respiratory system skin and connective tissue diseases Intensive care medicine Pharmacology business.industry Viral Vaccine fungi Respiratory disease Antiviral therapy Outbreak Viral Vaccines SARS-CoV medicine.disease body regions Severe acute respiratory syndrome-related coronavirus chemistry Drug Design Immunology Viral disease Coronavirus Infections business |
| Zdroj: | Antiviral Research |
| ISSN: | 0166-3542 |
| DOI: | 10.1016/j.antiviral.2005.03.002 |
| Popis: | A new disease, the severe acute respiratory distress syndrome (SARS), caused by the SARS coronavirus (SARS-CoV), emerged at the beginning of 2003 and rapidly spread throughout the world. Although the disease had disappeared in June 2003 its re-emergence cannot be excluded. The development of vaccines against SARS-CoV may take years. Therefore, the availability of effective antiviral drugs against SARS-CoV may be crucial for the control of future SARS outbreaks. In this review, experimental and clinical data about potential anti-SARS drugs is summarised and discussed. Animal model studies will be needed to help to determine which interventions warrant controlled clinical testing. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect